Kidney Function in Sickle Cell Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03277547|
Recruitment Status : Active, not recruiting
First Posted : September 11, 2017
Last Update Posted : March 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in kidney function, and to identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function.
"Funding Source - FDA OOPD"
|Condition or disease|
|Sickle Cell Disease Kidney Failure, Chronic|
Sickle cell disease is a severe monogenic disorder which affects approximately 80,000 patients in the US. It is characterized by a vasculopathy with involvement of multiple organs and resulting in complications such as ischemic stroke, pulmonary hypertension, autosplenectomy, priapism, as well as chronic kidney disease (CKD). Despite the high prevalence of CKD and its known association with increased mortality, the natural history of CKD and the factors associated with changes in kidney function in patients with SCD remain incompletely defined. Furthermore, the available treatment options for albuminuria, an early manifestation of CKD, in patients with SCD are limited. In fact, no controlled studies have confirmed the long-term efficacy of angiotensin-converting enzyme (ACE) inhibitors, the current "standard of care." There is increasing evidence for a contribution of endothelial dysfunction to the pathophysiology of albuminuria in SCD. The association of biomarkers of endothelial function with albuminuria provides opportunities, not only to assess the effect of therapies which improve endothelial function, but also to evaluate the predictive value of these biomarkers for a decline in kidney function. The long-range goal is to develop a model to identify patients at particularly high risk for a decline in kidney function.
In this study, the investigators will evaluate rate of change in kidney function (decline in estimated glomerular filtration rates and increase in albuminuria) and identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function. At the conclusion of this proposed work, the investigators will have an improved understanding of the natural history of CKD in sickle cell anemia. With the limited available therapies for the treatment of albuminuria in SCD and the paucity of data on the long-term efficacy of available pharmacotherapies, identification of biomarkers for the progression of CKD will facilitate the development of treatments which may be more effective than the current "standard of care."
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||The Association of Biomarkers of Endothelial Function With Prospective Changes in Kidney Function in Sickle Cell Anemia|
|Actual Study Start Date :||November 17, 2017|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||December 2023|
- Age- and sex-adjusted rate of change, over 36 - 48 months, in estimated glomerular filtration rate in patients with sickle cell anemia [ Time Frame: 36-48 months ]Estimated glomerular filtration rate will be ascertained using the CKD EPI equation
- Age- and sex-adjusted rate of change, over 36 - 48 months, in albuminuria in patients with sickle cell anemia [ Time Frame: 36-48 months ]Evaluate the rate of change in albuminuria by spot urine measurements of albumin-creatinine ratio during designated study visits
- Cross-sectional association of biomarkers of endothelial function with kidney function (estimated glomerular filtration rate and albuminuria) in patients with sickle cell anemia [ Time Frame: 36-48 months ]Plasma levels of ET-1, VEGF and soluble VCAM-1 from samples obtained at designated study visits will serve as measures of endothelial function
- Cross-sectional association of urine and plasma metabolomics profiles with kidney function (estimated glomerular filtration rates and albuminuria) in patients with sickle cell anemia [ Time Frame: 36-48 months ]Untargeted metabolic profiling of plasma and urine will be performed using high-resonance nuclear magnetic resonance spectrometry. Plasma and urine analytes which are significantly associated with estimated glomerular filtration rate and albumin-creatinine ratio will be ascertained.
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- age of 18 to 65 years;
- confirmed diagnosis of sickle cell anemia (HbSS and SB0 thalassemia);
- non-crisis, "steady state" with no severe pain episodes requiring medical contact during the preceding 4 weeks;
- ability to understand the requirements of the study and be willing to give informed consent.
- bone marrow transplantation;
- history of long-standing diabetes mellitus with suspicion for diabetic nephropathy as determined by a nephrologist;
- known diagnosis of hepatitis B or C infection (patients will not be screened specifically for this during the study);
- known HIV positive (patients will not be screened specifically for this);
- history of cancer, except non-melanoma skin cancer;
- pregnant or breastfeeding;
- connective tissue disease such as SLE;
- known glomerular disease unrelated to SCD;
- patients with ESRD on chronic dialysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03277547
|United States, North Carolina|
|University of North Carolina-Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|United States, Ohio|
|Ohio State Adult Sickle Cell Program|
|Columbus, Ohio, United States, 43210|
|United States, Tennessee|
|UTHSC Center for Sickle Cell Disease|
|Memphis, Tennessee, United States, 38163|
|Principal Investigator:||Kenneth Ataga, MD||UTHSC Center for Sickle Cell Disease|
|Responsible Party:||Kenneth Ataga MD, Professor, University of Tennessee|
|Other Study ID Numbers:||
1R01FD006030-01 ( U.S. FDA Grant/Contract )
|First Posted:||September 11, 2017 Key Record Dates|
|Last Update Posted:||March 6, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Kidney Failure, Chronic
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Renal Insufficiency, Chronic